Leinco Technologies (“Leinco”), a trusted source of high-quality primary and secondary antibodies, recombinant proteins, biological buffers, assay substrates and IVD raw materials, announces its acquisition of Genovis-owned QED Biosciences (“QED”), a leading provider of antibodies, kits, and recombinant proteins and antigens catering to the diverse needs of the IVD and research communities. In addition, QED complements Leinco’s suite of antibody development and other services, strategically targeting the IVD and research sectors.
Read the full article: Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services //
Source: https://www.prnewswire.com/news-releases/leinco-technologies-inc-acquires-qed-biosciences-leading-provider-of-antibodies-related-reagents-and-development-services-302236823.html